A Study of Brenipatide in Adult Participants With Schizophrenia
Phase 2
18–55
31 sites in AR, CA, CT +12
What this study is about
This Phase 2 study is focused on people with schizophrenia. The primary outcome being measured is Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²)
Secondary: Change from Baseline in Clinical Global Impression - Severity - Schizophrenia (CGI-S-SCH), Change from Baseline in Patient Global Impression - Severity, Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score, Change from Baseline on Neurocognitive Battery Composite Test Score at Week 36, Change from Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Total Score, Change from Baseline on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) Total Completion Time, Percentage of Participants with Body Mass Index ≥25 kg/m2 (BMI) Who Achieve Body Weight Reduction of ≥5%, Pharmacokinetic (PK): Average Steady State Plasma Concentration (Cavg) of Brenipatide
Psychiatry / Mental Health